SPC waiver: good intentions, but not the right deal?

Striking the perfect balance between incentivising innovation in drug development and widening access to medicines through generic competition is perhaps an unobtainable aim, but it’s an ideal that legislators and regulators must strive towards.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

The clinical trial dilemma: Navigating European practice

27 November 2025 Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.

Big Pharma

Report reveals surge of AI adoption in IP but lawyers remain cautious

20 November 2025 A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.

Big Pharma

Sun Pharma and BMS lead 2025 ANDA litigation

10 November 2025 According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.

More features

Novo Nordisk secures China win ahead of key patent expiration

Edwards v Meril: Inside the UPC’s landmark medtech showdown

Bird & Bird targets Nordic life sciences growth with regulatory hire

Key EU and UK regulatory changes to watch for in 2026

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

EU unveils sweeping pharma, biotech, and medical device reforms

SPC waiver: good intentions, but not the right deal?

More on this story

Editor's picks

Editor's picks

More features